{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:03:47Z","timestamp":1791601427902,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Canadian Immunodeficiencies Patient Organization"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with primary immunodeficiency (PID) are at increased risk for infections such as SARS-CoV-2 (COVID-19), due to the nature of their diseases and being immunocompromised. At this time, four vaccines against COVID-19 (Pfizer-BioNtech\u2019s Comirnaty<jats:sup>\u00ae<\/jats:sup>, Moderna\u2019s Spikevax<jats:sup>\u00ae<\/jats:sup>, AstraZeneca\u2019s Vaxzevria<jats:sup>\u00ae<\/jats:sup>, Johnson &amp; Johnson\u2019s Janssen<jats:sup>\u00ae<\/jats:sup>) have been approved for use by Health Canada. Due to the novelty of these vaccines, clinical studies in patients with PID are ongoing. Despite limited evidence, Canada\u2019s National Advisory Committee on Immunization (NACI) recommend that patients with PID without any contraindications should be vaccinated with any of the approved vaccines as the potential benefits of being immunized against the virus likely outweigh the risks of contracting a severe infection. The aim of this study was to understand the perceptions regarding COVID-19 vaccination among patients with PID and to identify specific factors related to vaccine hesitancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Canadian Immunodeficiencies Patient Organization (CIPO) conducted an online survey of its members to evaluate uptake of the COVID-19 vaccines by patients with PID. Data was collected using a self-administered online questionnaire. The survey was conducted between March and April 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At the time of survey, among 370 respondents who had not received the COVID-19 vaccine, 302 respondents (81.6%) indicated they were very or somewhat likely to get vaccinated against COVID-19; and 68 respondents (18.4%) indicated they were somewhat or very unlikely, undecided, or not planning to get vaccinated. A large majority of respondents indicated they had a diagnosis of PID (67.8%) and\/or specified their type of PID (27.7%). The most common reason for vaccine hesitancy was primarily due to uncertainty about immune response given an underlying immunodeficiency. Other concerns included unknown long-term side effects of COVID-19 vaccination, pre-existing history of allergic reactions, limited amount of data, lack of investigation of safety and effectiveness of COVID-19 vaccines in those with medical conditions, and skepticism of the underlying science and\/or the medical system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results point to the importance of ongoing patient outreach, education, and up-to-date information on the rapidly evolving scientific knowledge and evidence on COVID-19 relevant to the PID community, from clinical trials to real-world evidence and observational studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-022-00679-x","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T16:03:16Z","timestamp":1652112196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Understanding attitudes and obstacles to vaccination against COVID-19 in patients with primary immunodeficiency"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-6510","authenticated-orcid":false,"given":"Babak","family":"Aberumand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Ayoub Goulstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"issue":"Suppl 1","key":"679_CR1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1710-1492-7-S1-S11","volume":"7","author":"C McCusker","year":"2011","unstructured":"McCusker C, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S11.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"679_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/MOP.0000000000000833","volume":"31","author":"JE Walter","year":"2019","unstructured":"Walter JE, Ayala IA, Milojevic D. Autoimmunity as a continuum in primary immunodeficiency. Curr Opin Pediatr. 2019;31(6):851\u201362.","journal-title":"Curr Opin Pediatr"},{"issue":"3","key":"679_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","volume":"147","author":"AM Shields","year":"2021","unstructured":"Shields AM, Burns SO, Savic S, Richter AG, Anantharachagan A, Arumugakani G, Baker K, Bahal S, Bermingham W, Bhole M, Boules E. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J Allergy Clin Immunol. 2021;147(3):870\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"679_CR4","unstructured":"International Patient Organization for Primary Immunodeficiencies. Joint statement on the current coronavirus pandemic SARS-CoV-2\u2014COVID-19 in children and adult patients with Primary Immunodeficiencies (PID). Published February 13, 2020. https:\/\/ipopi.org\/wp-content\/uploads\/2021\/10\/COVID19_Joint_StatementUpdate5_20211028_FINAL.pdf. Accessed 15 Mar 2022."},{"issue":"2","key":"679_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","volume":"147","author":"I Meyts","year":"2021","unstructured":"Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, Lopez-Granados E, Gianelli C, Robles-Marhuenda A, Jeandel PY, Paillard C. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147(2):520\u201331.","journal-title":"J Allergy Clin Immunol"},{"issue":"6515","key":"679_CR6","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","volume":"370","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IK, Hodeib S, Korol C, Rosain J. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.","journal-title":"Science."},{"issue":"74","key":"679_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103705","volume":"1","author":"P Bergman","year":"2021","unstructured":"Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, S\u00f6derdahl G, \u00d6sterborg A, Smith CE, Wullimann D, Vesterbacka J. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;1(74): 103705.","journal-title":"EBioMedicine"},{"issue":"3","key":"679_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","volume":"148","author":"D Hagin","year":"2021","unstructured":"Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, Levi I, Benor S, Alcalay Y, Freund NT. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148(3):739\u201349.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"679_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaci.2021.11.022","volume":"149","author":"MN Pham","year":"2022","unstructured":"Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E, Lewis DB, Gernez Y. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. J Clinic Immunol. 2022;149(3):907\u201311.","journal-title":"J Clinic Immunol"},{"key":"679_CR10","unstructured":"National Advisory Committee on Immunization. Recommendations on the use of COVID-19 vaccines. Ottawa, Canada: Public Health Agency of Canada, Government of Canada. Published June 17, 2021. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines.html#t1. Accessed 28 June 2021."},{"key":"679_CR11","first-page":"E1620","volume":"192","author":"M Gates","year":"2021","unstructured":"Gates M, Pillay J, Wingert A, Guitard S, Rahman S, Zakher B, Gates A, Hartling L. Risk factors associated with severe outcomes of COVID-19: An updated rapid review to inform national guidance on vaccine prioritization in Canada. medRxiv. 2021;192:E1620.","journal-title":"medRxiv"},{"issue":"1","key":"679_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-021-00529-2","volume":"17","author":"TK Vander Leek","year":"2021","unstructured":"Vander Leek TK, Chan ES, Connors L, Derfalvi B, Ellis AK, Upton JE, Abrams EM. COVID-19 vaccine testing & administration guidance for allergists\/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021;17(1):1\u20136.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"34","key":"679_CR13","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","volume":"33","author":"NE MacDonald","year":"2015","unstructured":"MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161\u20134.","journal-title":"Vaccine"},{"key":"679_CR14","unstructured":"Frank K, Arim R. Canadians\u2019 willingness to get a COVID-19 vaccine: Group differences and reasons for vaccine hesitancy. Statistics Canada; 2020."},{"issue":"11","key":"679_CR15","first-page":"3505","volume":"14","author":"N Marcus","year":"2021","unstructured":"Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, Maoz-Segal R, Agmon-Levin N, Broides A, Nahum A, Rosenberg E. Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel. Front Immunol. 2021;14(11):3505.","journal-title":"Front Immunol"},{"key":"679_CR16","first-page":"230","volume":"198","author":"K Jab\u0142o\u0144ska","year":"2021","unstructured":"Jab\u0142o\u0144ska K, Aball\u00e9a S, Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. medRxiv. 2021;198:230\u20137.","journal-title":"medRxiv."},{"issue":"2","key":"679_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14785\/lymphosign-2021-0020","volume":"8","author":"CM Roifman","year":"2021","unstructured":"Roifman CM, Vong L. COVID-19 vaccination for patients with primary immunodeficiency. LymphoSign J. 2021;8(2):37\u201345.","journal-title":"LymphoSign J"},{"issue":"6","key":"679_CR18","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s10875-021-01046-y","volume":"41","author":"H Kinoshita","year":"2021","unstructured":"Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, et al. Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency. J Clin Immunol. 2021;41(6):1146\u201353.","journal-title":"J Clin Immunol"},{"key":"679_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029","author":"D Hagin","year":"2021","unstructured":"Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, Levi I, Benor S, Alcalay Y, Freund NT. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.029.","journal-title":"J Allergy Clin Immunol"},{"key":"679_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220289","author":"BJ Boyarsky","year":"2021","unstructured":"Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, Segev DL, Paik JJ. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Annals Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220289.","journal-title":"Annals Rheum Dis"},{"key":"679_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.05.21254656","author":"P Deepak","year":"2021","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, Liu Z. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.04.05.21254656.","journal-title":"medRxiv"},{"key":"679_CR22","unstructured":"National Advisory Co. COVID-19 vaccine: Canadian immunization guide. Ottawa, Canada: Public Health Agency of Canada, Government of Canada. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-26-covid-19-vaccine.html. Accessed 20 Mar 2022."},{"key":"679_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1603563","author":"M Guay","year":"2019","unstructured":"Guay M, Gosselin V, Petit G, Baron G, Gagneur A. Determinants of vaccine hesitancy in Quebec: a large population-based survey. Human Vaccin Immunother. 2019. https:\/\/doi.org\/10.1080\/21645515.2019.1603563.","journal-title":"Human Vaccin Immunother"},{"issue":"3","key":"679_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jadohealth.2021.06.003","volume":"69","author":"SH Adams","year":"2021","unstructured":"Adams SH, Schaub JP, Nagata JM, Park MJ, Brindis CD, Irwin CE Jr. Young adult perspectives on COVID-19 vaccinations. J Adolesc Health. 2021;69(3):511\u20134.","journal-title":"J Adolesc Health"},{"key":"679_CR25","unstructured":"Frank K, Arim R. Canadians\u2019 Willingness to Get a COVID-19 Vaccine: Group Differences and Reasons for Vaccine Hesitancy. . Ottawa, Canada Statistics Canada. Published August 25 2020. https:\/\/www150.statcan.gc.ca\/n1\/pub\/45-28-0001\/2020001\/article\/00073-eng.htm. Accessed 28 June 2021."}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-022-00679-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T16:03:52Z","timestamp":1652112232000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-022-00679-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1186\/s13223-022-00679-x","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All persons gave their informed consent prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent to participate obtained and available upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication obtained and available upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"38"}}